Submit global regulatory filings for CTX001 in TDT and SCD
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 May 2022
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex plans to submit global regulatory filings for CTX001 in TDT and SCD in late 2022.”
What we found
Evidence strength A What the grades mean
Later filings state that EU and UK regulatory submissions for exa-cel (CTX001) were completed in Q4 2022, with a US rolling submission initiated.
-
A Vertex Pharmaceuticals 8-K filed 2023-02-07
“In December 2022, Vertex completed regulatory submissions for exa-cel with the EMA and MHRA in the EU and the U.K., respectively.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In the fourth quarter of 2022, we completed European regulatory submissions for exa-cel and initiated a rolling submission in the United States” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“We completed regulatory submissions to the EMA and the MHRA for exa-cel for SCD and TDT in the fourth quarter of 2022” ✓ confirmed on the page
Market reaction: the shares moved -3.7% against the S&P 500 over the three sessions around the disclosure (6 Feb 2023 to 9 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Global regulatory filings for CTX001 in TDT and SCD
- Where
- Global
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “Partly met”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-VRTX-006510 · Corrections policy